Abstract:Abstract Background Ischemic coronary artery disease (CAD) is a major public health problem across the world. Early detection and appropriate management significantly reduced CAD-induced morbidities and death. Endothelial cells are pathogenically implicated. Purpose Our study was designed to investigate the role of the soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) in the in vitro protective effect of Metoprolol against hypoxia-induced injury of Human umbilical vein endothelial cells (HUVECs). Secondly, the clinical significance of variations in serum levels of sLOX-1 in patients with CAD was assessed. Methods In vitro, hypoxic injury model of HUVECs was established in an atmosphere of 1% O2, 95% N2, and 5% CO2 for 24 hours. The protective effect and mechanism of action of the cardio-selective beta-blocker Metoprolol at 10–6 μM concentration was investigated. Consented stable atherosclerotic CAD (n=150) and unstable angina pectoris patients (n=75) along with 150 healthy volunteer subjects were voluntarily enrolled in this ethically approved study. Invasive coronary angiogram with ≥50% stenosis at least in one major coronary artery was used for diagnosis. ESC/ACC/AHC/practical protocols were used for categorizing patients into stable or unstable CAD. Serum sLOX-1 level was measured using specific ELISA kit. The diagnostic significance of serum sLOX-1 levels was assessed by analyzing its area under the curve (AUC). Results In vitro hypoxic conditions induced high rate of cellular apoptosis, high levels of LOX-1 expression, reactive oxygen species (ROS) generation and LDH release from HUVECs after 24 hours incubation, compared to normoxic control cells. Metoprolol significantly decreased LOX-1 levels, and prevented the release of LDH and generation of ROS. This culminated into marked improvement in cellular viability of hypoxia-exposed HUVECs (p<0.001). Compared to healthy subjects, serum levels of sLOX-1s were significantly elevated in atherosclerotic stable and unstable CAD patients (p<0.001). Serum sLOX-1 levels were increased by 4.21 folds in stable CAD patients and by 6.373 folds in atherosclerotic unstable angina patients vs. healthy participants. Moreover, the levels in the two patients' groups were significantly different (p<0.001). In stable angina CAD patients, sLOX-1 AUC = 0.929; and in unstable CAD patients, AUC = 0.944, indicating that serum sLOX-1 levels clearly differentiated patients from healthy participants with high specificity and sensitivity. Conclusions Extrapolated from HUVECs hypoxia-induced injury model and the protective effect of Metoprolol, elevation of the circulating levels of sLOX-1 correlated with increased risks for atherosclerotic CAD and is a highly sensitive and specific biomarker for early detection of the disease. Funding Acknowledgement Type of funding source: None

Changes and clinical significance of serum sLOX-1 and omentin-1 in patients with H-type hypertension complicated with acute ischemic stroke

Dynamic Changes and Prognostic Value of Gut Microbiota-Dependent Trimethylamine-N-Oxide in Acute Ischemic Stroke.

[Value of Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1) and LOX-1 Mrna in Peripheral Mononuclear Cells in Early Diagnosis of Acute Coronary Syndrome].

Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Level is Related to Clinical Prognosis in Patients with Acute Atherosclerosis-related Ischemic Stroke

Analysis of correlation between oxidized low density lipoprotein and thrombus precursor protein with acute cerebral infarction

The clinical impact of serum sLOX-1 level in coronary artery disease patients as inferred from its implication in the in vitro protective effects of metoprolol against hypoxic injury of HUVECs

Relationship of Soluble Lectin-Like Oxidized LDL Receptor 1 with Severe Obstructive Sleep Apnea-Hypopnea Syndrome in Men

Research of the Relevance Between Serum Slox-1 Levels and Left Ventricular Diastolic Function in Patients with Essential Hypertension

Changes in the contents of nitrogen monoxide in serum and endothelin in plasma associated with the prognosis for patients with stroke

Impact of Serum Omentin-1 Levels on Functional Prognosis in Nondiabetic Patients with Ischemic Stroke.

Plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 acts as a new biomarker for NSTEMI and STEMI patients

Change of Plasma Oxidized Low-Density Lipoprotein Level Predicts Clinical Outcome at 90 Days for Patients with Acute Ischemic Stroke

Analysis on correlation between serum Lp-PLA2 level with ischemic stroke occurrence and prognosis in patients with hypertension

Relationship between serum sLOX-1 level with leptin and coronary slow flow

Analysis of changes and relationship of LPA and HCY with prognosis in acute stroke patients

Correlation of sLOX-1 Levels and MR Characteristics of Culprit Plaques in Intracranial Arteries with Stroke Recurrence

Clinical relevance of serum omentin‐1 levels as a biomarker of prognosis in patients with acute cerebral infarction

Serum Heme Oxygenase-1 Predicts Clinical Outcome and Hemorrhagic Transformation after Acute Ischemic Stroke

Association of the LOX-1 Rs1050283 Polymorphism with Risk for Atherosclerotic Cerebral Infarction and Its Effect on Slox-1 and LOX-1 Expression in a Chinese Population

Changes of Serum Oxidized Low-Density Lipoprotein in Patients with Acute and Non-Acute Coronary Artery Disease

Serum heme oxygenase‐1 level predicts clinical outcome after acute ischemic stroke